The company reported earnings 30 days ago and faces significant headwinds including a Department of Justice probe into Medicare billing, political uncertainty from new healthcare plans, and commission cuts. However, it maintains solid revenue growth and a 2.7% dividend yield. A prominent billionaire sold most of his position, while Reddit investors are buying it as a top non-AI stock. The recent appointment of a former FDA commissioner to the board aims to strengthen leadership amid regulatory challenges. The stock has declined 7.2% since last earnings and lags behind the Nasdaq.